Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
We report a patient with acquired immune deficiency syndrome (AIDS) who developed Philadelphia-positive chronic myeloid leukemia (CML) and was successfully treated with imatinib mesylate. He achieved a complete cytogenetic response after 7 months of treatment. It appears that there is no in vivo interaction between imatinib and highly active anti-retroviral therapy (HAART) and these drugs can be concurrently administered with safety to patients with CML and AIDS.
Tsimberidou
Apostolia-Maria
AM
Department of Leukemia, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA. atsimber@mdanderson.org
Medina
Jorge
J
Cortes
Jorge
J
Rios
Adan
A
Bonnie
Glisson
G
Faderl
Stefan
S
Kantarjian
Hagop
H
Garcia-Manero
Guillermo
G
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use; D001549:Benzamides; D020732:Cytogenetic Analysis; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*
D000998:Antiviral Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases